EC
SUPN icon

Elmind Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Elmind Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.26M Buy
70,000
+50,000
+250% +$2.4M 0.82% 25
2026
Q1 		$1.03M Hold
20,000
– – 0.29% 33
2025
Q4 		$994K Buy
+20,000
New +$972K 0.29% 33

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Elmind Capital's SUPN Position: Q2 2026 in Review

Elmind Capital increased its Supernus Pharmaceuticals (SUPN) stake by 250% in Q2 2026, buying an estimated $2.4M and bringing the position to 70,000 shares worth $3.26M. The position accounts for 0.82% of the portfolio, ranked #25.

Elmind Capital first reported a position in SUPN in Q4 2025 and has held it in 3 quarters since. 333 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Elmind Capital held 70,000 shares of Supernus Pharmaceuticals worth $3.26M as of Q2 2026.
  • Elmind Capital bought 50,000 Supernus Pharmaceuticals shares in Q2 2026, an estimated $2.4M.
  • Supernus Pharmaceuticals made up 0.82% of Elmind Capital's portfolio in Q2 2026, its #25 holding.
  • Elmind Capital first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.